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Trp-rich model antimicrobial peptideTo develop novel short Trp-rich antimicrobial peptides (AMPs) with potent cell speciﬁcity (targeting bacteria
but not eukaryotic cells) and anti-inﬂammatory activity, a series of 11-meric Trp-rich model peptides with
different ratios of Leu and Lys/Arg residues, XXWXXWXXWXX-NH2 (X indicates Leu or Lys/Arg), was
synthesized. K6L2W3 displayed an approximately 40-fold increase in cell speciﬁcity, compared with the
natural Trp-rich AMP indolicidin (IN). Lys-containing peptides (K8W3, K7LW3 and K6L2W3) showed
approximately 2- to 4-fold higher cell speciﬁcities than did their counterparts, the Arg-containing peptides
(R8W3, R7LW3 and R6L2W3), indicating that multiple Lys residues are more important than multiple Arg
residues in the design of AMPs with good cell speciﬁcity. The excellent resistance of D-enantiomers (K6L2W3-
D and R6L2W3-D) and Orn/Nle-containing peptides (O6L2W3 and O6L2W3) to trypsin digestion compared
with the rapid breakdown of the L-enantiomers (K6L2W3 and R6L2W3), highlights the clinical potential of
such peptides. K6L2W3, R6L2W3, K6L2W3-D and R6L2W3-D caused weak dye leakage from bacterial
membrane-mimicking negatively charged EYPG/EYPE (7:3, v/v) liposomes. Confocal microscopy showed
that these peptides penetrated the cell membrane of Escherichia coli and accumulated in the cytoplasm, as
observed for buforin-2. Gel retardation studies revealed that the peptides bound more strongly to DNA than
did IN. These results suggested that one possible peptide bactericidal mechanism may relate to the inhibition
of intracellular functions via interference with DNA/RNA synthesis. Furthermore, some model peptides,
containing K6L2W3, K5L3W3, R6L2W3, O6L2W3, O6L2W3, and K6L2W3-D inhibited LPS-induced inducible nitric
oxide synthase (iNOS) mRNA expression, the release of nitric oxide (NO) following LPS stimulation in
RAW264.7 cells and had powerful LPS binding activities at bactericidal concentrations. Collectively, our
results indicated that these peptides have potential for future development as novel antimicrobial and anti-
inﬂammatory agents.© 2009 Elsevier B.V. All rights reserved.1. Introduction
A rapid increase in the emergence of bacteria resistant to
conventionally used antibiotics has occurred in recent years. The
increasing prevalence of multidrug-resistant bacteria necessitates
the development of new antibiotics to combat infections by these
bacteria [1–4]. Antimicrobial peptides (AMPs), isolated from a wide
range of animal, plant, and bacterial species, are ubiquitous in natureMolecular Medicine, School of
el.: +82 62 230 6769; fax: +82
ll rights reserved.and are thought to be important in innate immunity and host defenses
against infectious agents [1–4]. Because of their rapid killing action,
highly selective toxicity, and because bacteria cannot easily develop
resistance against the peptides, AMPs are considered as potential
alternatives to conventional antibiotics [5,6]. Most AMPs do not target
speciﬁc molecular receptors of pathogens but rather interact with and
permeabilize microbial membranes [7,8].
A comparison of AMP sequences reveals that two types of side
chains are essential for antimicrobial activity. Cationic side chains,
such as those of Arg and Lys, are thought to mediate peptide
interactions with negatively charged membranes and/or cell walls
of Gram-negative bacteria [9–12]. Bulky hydrophobic side chains,
such as those of Ile, Leu, Phe, or Trp, occur frequently in AMPs,
presumably providing lipophilic anchors that ultimately induce
membrane disruption [9–12]. It has been reported that the
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hydrophobicity of residues, and there should be a proper balance
between cationic and hydrophobic residues to avoid toxicity toward
mammalian cells [9–12].
In recent years, there has been an increasing interest in under-
standing the mechanisms of action of short Trp-rich peptides [13–16].
Trp has a strong ability to insert into membranes and Trp-rich
peptides partition into membranes [13,14]. A well-studied example of
a Trp-rich peptide is the 13-meric indolicidin (IN) isolated from the
cytoplasmic granules of bovine neutrophils [17]. Although IN displays
activity against a wide range of targets, including Gram-positive and
Gram-negative bacteria, fungi, and protozoa, the relatively high
toxicity of IN towardmammalian cells prevents its use as an antibiotic.
Therefore, much effort has been directed to decreasing toxicity for
mammalian cells and to improving IN antimicrobial activity [18–21].
In this study, we designed novel Trp-rich model AMPs with high
antimicrobial activities, coupled with no or less hemolytic activities
(i.e. with higher cell speciﬁcity/therapeutic index), and that were
shorter in length than the natural Trp-rich AMP IN. A series of 11-mer
cationic Trp-rich model peptides, with different ratios of Lys and Leu
residues, andwith the structure XXWXXWXXWXX-NH2 (X represents
Leu or Lys), was synthesized. All these peptides (K8W3, K7LW3, K7LW3,
K6L2W3, K5L3W3, K4L4W3, K3L5W3 and K2L6W3) have net positive
charges, ranging between +3 and +9, and have different hydro-
phobicities. To investigate the functional difference between Lys and
Arg in the cell speciﬁcity of cationic Trp-rich model peptides,
Lys→Arg substitution analogs (R8W3, R7LW3 and R6L2W3) were also
prepared. In addition, to increase the stability of the peptides to
endogenous proteases, D-enantiomers (K6L2W3-D and R6L2W3-D)
with D-amino acids, and two analogs (O6L2W3 and O6X2W3)
containing Orn and/or Nle, were constructed. Antimicrobial activ-
ities against Gram-positive and Gram-negative bacterial strains
including antibiotic-resistant clinical isolates, and the ability of
peptides to cause hemolysis, were examined. Tryptophan ﬂuores-
cence spectroscopy was used to explore the speciﬁcities of peptides
for liposomes that mimicked bacterial or eukaryotic cells. Further-
more, the mechanisms by which the peptides killed bacteria were
investigated by measuring peptide ability to cause leakage of a
ﬂuorescent dye from bacterial membranes-mimicking lipid vesicles.
In addition, to determine peptide localization, confocal microscopy
was performed after treatment of a wild-type Escherichia coli strain
with FITC-labeled peptides.
Lipopolysaccharide (LPS; endotoxin) is the major outer surface
membrane component of almost all Gram-negative bacteria and acts
as an extremely strong stimulator of mononuclear phagocytes
(monocytes and macrophages), which are part of the innate immune
system of diverse eukaryotic species ranging from insects to humans
[22,23]. The activationmechanism of macrophages by LPS starts when
LPS binds with LPS-binding protein (LBP), accelerating the binding of
CD14, the primary receptor of LPS, which is expressed mainly on
macrophages [24]. The LPS-LBP-CD14 complex initiates intracellular
signaling by interacting with the transmembrane protein Toll-like
receptor-4 (TLR-4), which activates the NF-κB transcription factor,
resulting in the production and secretion of inﬂammatory cytokines,
including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric
oxide (NO) and others [24–26].
Recent studies have demonstrated that in addition to their
antimicrobial activities, a few cathelicidin-derived AMPs, such as
LL-37, IN, bactenecin, BMAP-27, and β-defensin, have the potential to
inhibit LPS-induced cellular cytokine and/or nitric oxide (NO) release
by binding directly to LPS or by blocking the binding of LPS to
LPS-binding protein (LBP) [24–31]. These propertiesmake these AMPs
attractive drug candidates for treatment of endotoxin shock and sepsis
caused by Gram-negative bacterial infections [24–31].
Therefore, to investigate whether our designed antimicrobial
peptides showanti-inﬂammatory activities when testedwith immunecells, peptide inhibition of NO production and iNOS mRNA expression
in LPS-stimulated mouse macrophage RAW264.7 cells were exam-
ined. LPS binding activities of IN and analogs were explored by the
chromogenic Limulus amebocyte lysate (LAL) assay. These results will
help in the design of novel short antimicrobial peptides with potent
antimicrobial and anti-inﬂammatory activities.
2. Materials and methods
2.1. Materials
Rink amide 4-methylbenzhydrylamine (MBHA) resin, ﬂuoren-9-
yl-methoxycarbonyl (Fmoc)-amino acids and other reagents for the
peptide synthesis were purchased fromCalbiochem-Novabiochem (La
Jolla, CA). Egg yolk L-phosphatidylcholine (EYPC), egg yolk L-
phosphatidylethanolamine (EYPE), egg yolk L-phosphatidyl-DL-gly-
cerol (EYPG), LPS (lipopolysaccharide from E. coli O111:B4), calcein,
gramicidin D (GD), trypsin (from bovine pancreas, EC 3.4.21.4) and
polymyxin B were supplied by Sigma Chemical Co (St. Louis, MO).
DMEM and fetal bovine serum (FBS) were supplied by HyClone
(SeouLin, Bioscience, Korea). RAW 264.7 cells were purchased from
American Type Culture Collection (Bethesda, MD). All other reagents
were of analytical grade. The buffers were prepared in double glass-
distilled water.
2.2. Peptide synthesis
Peptides listed in Table 1 were prepared using the standard Fmoc-
based solid-phase synthesis technique on Rink amide MBHA resin
support. DCC (dicyclohexylcarbodiimide) and HOBt (N-hydroxyben-
zotriazole) were used as coupling reagents, and ten-fold excess Fmoc-
amino acids added during every coupling cycle. After cleavage and
deprotection with a mixture of triﬂuoroacetic acid/water/thioani-
sole/phenol/ethanedithiol/triisopropylsilane (81.5:5:5:5:2.5:1, v/v)
for 2 h at room temperature, crude peptides were repeatedly extracted
with diethyl ether and puriﬁed by reverse-phase HPLC on a
preparative Vydac C18 column (15 μm, 20×250 mm) using an
appropriate 0–90% water/acetonitrile gradient in the presence of
0.05% triﬂuoroacetic acid. The ﬁnal purity of the peptides (N98%) was
assessed by reverse-phase HPLC on an analytical Vydac C18 column
(4.6×250 mm, 300 Å, 5-μm particle size). The molecular masses of
puriﬁed peptides were determined using MALDI-TOF MS (matrix-
assisted laser-desorption ionization-time-of-ﬂight mass spectrome-
try) (Shimadzu, Japan). Peptide concentrations were determined by
amino acid analysis (Hitachi Model, 8500 A, Japan) and relative
hydrophobicity measured from the retention times on a C18 reverse-
phase analytical column.
2.3. Antimicrobial activity (MIC)
The antibacterial activities of peptides against three Gram-positive
bacterial strains and three Gram-negative bacterial strains were
examined in sterile 96-well plates with the broth microdilution
method. Aliquots (100 μl) of a bacterial suspension at 2×106 colony-
forming units (CFU)/ml in 1% peptonewere added to 100 μl of peptide
solution (serial 2-fold dilutions in 1% peptone). After incubation for
18–20 h at 37 °C, bacterial growth inhibition was determined by
measuring absorbance at 600 nmwith aMicroplate autoreader EL 800
(Bio-Tek Instruments). The minimal inhibitory concentration (MIC) is
deﬁned as the minimum peptide concentration that inhibits bacteria
growth. Three types of Gram-positive bacteria (Bacillus subtilis [KCTC
3068], Staphylococcus epidermidis [KCTC 1917] and Staphylococcus
aureus [KCTC 1621]) and three types of Gram-negative bacteria
(Escherichia coli [KCTC 1682], Pseudomonas aeruginosa [KCTC 1637]
and Salmonella typhimurium [KCTC 1926]) were procured from the
Korean Collection for Type Cultures (KCTC) at the Korea Research
Table 1
Amino acid sequences, calculated and observed molecular masses, net charges, and RP-HPLC retention times of the Trp-rich model peptides designed and synthesized in this study.
Peptides Amino acid sequences Molecular MS Net charge Retention times (RT)b
Calculated Measureda
K8W3 KKWKKWKKWKK-NH2 1601.1 1601.0 +9 16.00
K7LW3 KLWKKWKKWKK-NH2 1586.0 1585.7 +8 17.85
K6L2W3 KLWKKWKKWLK-NH2 1571.0 1570.4 +7 20.92
K5L3W3 KLWKLWKKWLK-NH2 1556.0 1555.3 +6 24.03
K4L4W3 KLWKLWLKWLK-NH2 1540.9 1541.7 +5 27.61
K3L5W3 KLWKLWLKWLL-NH2 1525.9 1525.7 +4 31.87
K2L6W3 KLWLLWLKWLL-NH2 1510.9 1511.8 +3 36.44
R8W3 RRWRRWRRWRR-NH2 1825.1 1825.7 +9 19.55
R7LW3 RLWRRWRRWRR-NH2 1782.1 1782.3 +8 19.30
R6L2W3 RLWRRWRRWLR-NH2 1739.1 1739.7 +7 21.56
O6L2W3 OLWOOWOOWLO-NH2 1486.9 1487.3 +7 20.54
O6X2W3 OXWOOWOOWXO-NH2 1486.9 1486.7 +7 20.83
K6L2W3-D klwkkwkkwlk-NH2 1571.0 1571.2 +7 21.00
R6L2W3-D rlwrrwrrwlr-NH2 1739.1 1738.9 +7 21.69
Indolicidin (IN) ILPWKWPWWPWRR-NH2 1909.3 1909.3 +4 29.63
a Molecular masses were determined by MALDI-TOF-MS. O and X indicate Orn (ornithine) and Nle (norleucine), respectively. Small letters represent D-type amino acids.
b Retention time (RT) wasmeasured using a C18 reverse-phase analytical column (5 μm; 4.6×250mm; Vydac). Peptides were eluted for 60min, using a linear gradient of 0% to 90%
(v/v) acetonitrile in water containing 0.05% (v/v) triﬂuoroacetic acid.
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resistant Staphylococcus aureus (MRSA) (CCARM 3001 and CCARM
3543) and multidrug-resistant Pseudomonas aeruginosa (MDRPA)
(CCARM 2095 and CCARM 2109) were obtained from the Culture
Collection of Antibiotic-Resistant Microbes (CCARM) at Seoul
Women's University in Korea.
2.4. Hemolytic activity (MHC)
Fresh human red blood cells (hRBCs) were washed 3 times with
PBS (35 mM phosphate buffer, 0.15 M NaCl, pH 7.4) by centrifugation
for 7 min at 1000×g, and resuspended in PBS. The peptide solutions
(serial 2-fold dilutions in PBS) were added to 100 ml of hRBC
suspension [4% (v/v) in ﬁnal] in PBS to a ﬁnal volume of 200 μl, and
incubated for 1 h at 37 °C. Samples were centrifuged at 1000×g for
5 min, and hemoglobin release monitored by measuring supernatant
absorbance at 405 nm with Microplate ELISA Reader. MHC is deﬁned
as the minimal peptide concentration that producing 5% hemolysis. As
negative and positive controls, hRBCs in PBS (Ablank) and 0.1% Triton X-
100 (Atriton) were employed, respectively. The hemolysis percentage
was calculated according to the equation:
% hemolysis = 100 × Asample − Ablank
 
= Atriton − Ablankð Þ
h i
2.5. Resistance to proteolytic digestion
Bacteria (E. coli and S. aureus) were grown overnight for 18 h at
37 °C in 10 ml of LB broth and then 10 μl of this culture was inoculated
into 10 ml of fresh LB and incubated for an additional 3 h at 37 °C to
obtainmid-logarithmic phase organisms. For the radial diffusion assay
method, a bacteria suspension (2×106 CFU/ml in LB) was mixed with
0.7% agarose. The mixture was poured into a 10-cm petri dish after
rapidly dispersing. Five microliters of an aqueous peptide stock
solution (10mg/mL)were added to 25 μl of 0.2 μg/ml trypsin solution
in PBS, receptively, and incubated at 37 °C for 6 h. The reaction was
stopped by freezing with liquid nitrogen, and then ten-microliters
aliquots were placed in each circle paper (≈6mm in diameter) put on
the agarose plates and then incubated at 37 °C for overnight. The
diameters of the bacterial clearance zones surrounding the circle
paper were measured for the quantitation of inhibitory activities. For
the broth microdilution assay method, aliquots (100 μl) of a bacterial
suspension (2×106 CFU/ml in 1% peptone) were added to 100 μl ofeach peptide in 1% peptone (ﬁnal peptide concentration: 2× MIC for
bacteria). After incubation for 18–20 h at 37 °C, bacterial growth
inhibitionwas determined bymeasuring absorbance at 600 nmwith a
Microplate autoreader EL 800 (Bio-Tek Instruments).
2.6. Preparation of small unilamellar vesicles (SUVs)
Small unilamellar vesicles were prepared with a standard
procedure using the required amounts of EYPE/EYPG (7:3, w/w) or
EYPC/cholesterol (10:1, w/w) for tryptophan ﬂuorescence. Dry lipids
were dissolved in chloroform in a small glass vessel. Solvents were
removed by rotary evaporation to form a thin ﬁlm on the wall of a
glass vessel and lyophilized overnight. Dried thin ﬁlms were
resuspended in Tris–HCl buffer by vortex mixing. Lipid dispersions
were sonicated on ice water for 10–20 min with a titanium-tip
ultrasonicator until the solution became transparent.
2.7. Tryptophan ﬂuorescence blue shift
The ﬂuorescence emission spectrum of tryptophan of peptides was
monitored in aqueous Tris–HCl buffer, Tris–HCl buffer containing
1.5 M NaCl and in the presence of vesicles composed of either EYPE/
EYPG (7:3 w/w) SUVs or EYPC/cholesterol (10:1 w/w) SUVs. In these
ﬂuorometric studies, small unilamellar vesicles (SUVs) were used to
minimize differential light scattering effects [32,33]. Tryptophan
ﬂuorescence measurements were obtained using a model RF-
5301PC spectrophotometer (Shimadzu, Japan). Each peptide was
added to 3 ml of Tris–HCl buffer (10 mM Tris, 0.1 mM EDTA, 150 mM
NaCl, pH 7.4) containing 0.6 mM liposomes (pH 7.4), and the peptide/
liposome mixture (molar ratio of 1:200) allowed to interact at 20 °C
for 10 min. The ﬂuorescence was excited at 280 nm, and emission
scanned from 300 to 400 nm.
2.8. Dye leakage
Calcein-entrapped LUVs composed of EYPE/EYPG (7:3, w/w)
were prepared by vortexing the dried lipid in dye buffer solution
(70 mM calcein, 10 mM Tris, 150 mM NaCl, 0.1 mM EDTA, pH 7.4).
The suspension was subjected to 10 frozen-thaw cycles in liquid
nitrogen and extruded 21 times through polycarbonate ﬁlters (two
stacked 100-nm pore size ﬁlters) with a LiposoFast extruder
(Avestin, Inc., Canada). Untrapped calcein was removed by gel
ﬁltration on a Sephadex G-50 column. The concentration of calcein-
entrapped LUVs was determined in triplicate by phosphorus
Table 2
Minimal inhibitory concentrations (MICs) of the peptides against Gram-negative and Gram-positive bacterial strains.
Peptide MICa (μM)
Gram-negative bacteria Gram-positive bacteria
E. coli
[KCTC 1682]
P. aeruginosa
[KCTC 1637]
S. typhimurium
[KCTC 1926]
B. subtilis
[KCTC 3068]
S. epidermidis
[KCTC 1917]
S. aureus
[KCTC 1621]
K8W3 4 2 1 2 2 4
K7LW3 2 2 1 2 2 4
K6L2W3 2 2 1 2 2 2
K5L3W3 2 2 1 4 2 2
K4L4W3 4 4 2 4 4 2
K3L5W3 8 8 4 8 8 4
K2L6W3 32 16 32 32 32 32
R8W3 8 8 4 4 2 8
R7LW3 8 8 4 4 2 4
R6L2W3 8 8 2 4 2 4
O6L2W3 2 4 2 4 2 4
O6X2W3 2 4 2 2 2 4
K6L2W3-D 4 4 2 4 4 4
R6L2W3-D 4 4 2 2 4 2
Indolicidin (IN) 4 8 4 2 8 4
Table 3
Cell speciﬁcities (therapeutic indices) of the peptides used in this study.
Peptide GM (μM)a MHC (μM)b Therapeutic Index (TI)c
(MHC/GM)
K8W3 2.5 400b 320.0
K7LW3 2.2 400b 363.6
K6L2W3 2.0 400b 400.0
K5L3W3 2.2 100 45.5
K4L4W3 3.3 6.25 1.9
K3L5W3 6.7 3.125 0.5
K2L6W3 29.3 1.56 0.1
R8W3 5.6 400b 142.8
R7LW3 5.0 400b 160.0
R6L2W3 4.6 400 86.9
O6L2W3 3.0 400b 266.6
O6X2W3 2.6 400 153.8
K6L2W3-D 3.6 400 111.1
R6L2W3-D 3.0 400 133.3
Indolicidin (IN) 4.8 50 10.4
a The geometric mean (GM) of the MIC values of the peptides acting against all six
bacterial strains shown in the table.
b The MHC (minimal hemolytic concentration) is the peptide concentration causing
5% hemolysis.
c The ratio of the MHC (μM) to the geometric mean MIC (μM). Larger values indicate
greater cell speciﬁcity.
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measuring ﬂuorescence intensity at an excitation wavelength of
490 nm and emission wavelength of 520 nm on a model RF-5301PC
spectrophotometer. For determination of 100% dye-release, 20 μl
10% Triton-X100 in Tris-buffer was added to dissolve the vesicles.
The percentage of dye leakage caused by the peptides was
calculated as follows:
% Dye leakage = 100 × F − F0ð Þ= Ft − F0ð Þ½ 
where F is the ﬂuorescence intensity achieved at 5 min after peptide
addition, and F0 and Ft represent ﬂuorescence intensities without the
peptides and with Triton X-100, respectively.
2.9. Confocal laser-scanning microscopy
E. coli cultures were grown to the mid-logarithmic phase. E. coli
cells (107 CFU/ml) in 10 mM PBS, pH 7.4 were incubated with FITC-
labeled peptides (5 μg/ml) at 37 °C for 30 min. Next, cells were
washed with PBS and immobilized on a glass slide. FITC-labeled
peptides were observed with an Olympus IX 70 confocal laser-
scanning microscope (Japan). Fluorescent images were obtained with
a 488-nm band-pass ﬁlter for FITC excitation.
2.10. DNA binding assay
Gel retardation experiments were performed by mixing 100 ng of
the plasmid DNA (pBluescript II SK+) with increasing amounts of
peptide in 20 μl of binding buffer (5% glycerol, 10 mM Tris–HCl, pH 8.0,
1 mM EDTA, 1 mM dithiothreitol, 20 mM KCl, and 50 μg/ml bovine
serum albumin). Reaction mixtures were incubated at room tem-
perature for 1 h. Subsequently, 4 μl of native loading buffer was added
(10% Ficoll 400, 10 mM Tris–HCl, pH 7.5, 50 mM EDTA, 0.25%
bromophenol blue, and 0.25% xylene cyanol), and a 20 μl aliquot
subjected to 1% agarose gel electrophoresis in 0.5×Tris borate-EDTA
buffer (45 mM Tris-borate and 1 mM EDTA, pH 8.0). The plasmid DNA
used was puriﬁed by CsCl-gradient ultracentrifugation to select the
closed circular form of the plasmid.
2.11. Cell culture
RAW 264.7 cells were purchased from the American Type Culture
Collection (Manassas, VA) and cultured in DMEM supplemented with
10% fetal bovine serum and antibiotic–antimyotic solution (100 U/ml
penicillin, 100 g/ml streptomycin and 25 g amphotericin B) in 5% CO2at 37 °C. Cultures were passed every 3 to 5 days, and cells were
detached by brief trypsin treatment, and visualized with an inverted
microscope.
2.12. Cytotoxicity (MTT proliferation assay)
Cytotoxicity of peptides against RAW 264.7 cells was determined
using the MTT assay as reported previously [35], with minor
modiﬁcations. RAW 264.7 cells were seeded on 96-well microplates
at a density of 2×104 cells/well in 150 μl DMEM containing 10% fetal
bovine serum. Plates were incubated for 24 h at 37 °C in 5% CO2.
Peptide solutions (20 μl) (serial 2-fold dilutions in DMEM) were
added, and the plates further incubated for 2 days. Wells containing
cells without peptides served as controls. Subsequently, 20 μl MTT
solution (5 mg/ml) was added in each well, and the plates were
incubated for a further 4 h at 37 °C. Precipitated MTT formazan was
dissolved in 40 μl of 20% (w/v) SDS containing 0.01 M HCl for 2 h.
Absorbance at 570 nmwas measured using a microplate ELISA reader
(Molecular Devices, Sunnyvale, CA). Cell survival was expressed as a
percentage of the ratio of A570 of cells treated with peptide to that of
cells only.
Fig. 1. Relationships of cationicity and hydrophobicity of the peptides between and antimicrobial activity and hemolytic activity. The line was ﬁtted by the linear regression. Each
point represents one peptide.
Table 4
Antimicrobial activities of peptides against antibiotic-resistant clinical isolates.
Peptides MIC (μM)a
MRSA 1b
[CCARM 3001]
MRSA 2
[CCARM 3543]
MDRPA 1c
[CCARM 2095]
MDRPA 2
[CCARM 2109]
K8W3 8 4 8 8
K7LW3 8 4 8 8
K6L2W3 4 2 8 8
K5L3W3 4 4 4 8
K4L4W3 8 4 16 16
K3L5W3 4 4 8 16
K2L6W3 64 32 64 N 64
R8W3 8 4 16 16
R7LW3 8 2 16 16
R6L2W3 8 2 16 16
O6L2W3 8 2 8 16
O6X2W3 8 2 8 16
K6L2W3-D 8 2 16 32
R6L2W3-D 8 2 16 32
Indolicidin (IN) 8 8 32 32
a Determined in three independent experiments, each performed in triplicate.
b Methicillin-resistant Staphylococcus aureus.
c Multidrug-resistant Pseudomonas aeruginosa.
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Nitrite accumulation in culture media was used as an indicator of
nitric oxide (NO) production [36]. Cells were plated at a density of
5×105 cells ml−1 in 96-well culture plates, and stimulated with LPS
(20 ng/ml) from E. coli O111:B4 (Sigma) in the presence or absence of
peptides for 24 h. Isolated supernatant fractions were mixed with an
equal volume of Griess reagent (1% sulfanilamide, 0.1% naphthylethy-
lenediamine dihydrochloride, and 2% phosphoric acid) and incubated
at room temperature for 10 min. Nitrite production was measured by
absorbance at 540 nm, and the concentrations were determined using
a standard curve generated with NaNO2.
2.14. Determination of iNOS mRNA expression
RAW 264.7 cells were plated in six-well plates (5×105 cells/well)
and cultured overnight. Cells were stimulated without (negative
control) or with 20 ng/ml LPS in the presence or absence of peptide in
DMEM supplemented with 10% bovine serum for 3 h. After
stimulation, the cells were detached from the wells and washed
once with phosphate-buffered saline (PBS). Competitive RT-PCR was
performed as described previously [37]. Brieﬂy, total RNA was
extracted using TriReagent (Molecular Research Center, Cincinnati,
OH) according to the manufacturer's instructions. RNA samples were
used as the template in RT-PCR. The cDNA products of iNOS were
ampliﬁed in the presence of 3′ (5′-CTGCAGCACTTGGATCAGGAACCTG-
3′) and 5′ (5′-GGGAGTAGCCTGTGTGCACCTGGAA-3′) primers. Equal
amounts of RNA were reversely transcribed into cDNA with oligo(dT)
15 primers. PCRwas performedwith cDNA and individual primers. For
competitive RT-PCR analysis of iNOS mRNA, we used an internal
standard, speciﬁcally, a cDNA fragment with the central 80 bp deleted.
Samples were heated to 94 °C for 5 min, and cycled 40 times at 94 °C
for 1 min, 55 °C for 1.5 min, and 94 °C for 1 min, followed by anadditional extension step of 72 °C for 5 min. The PCR-ampliﬁed
products were electrophoresed on an 8% polyacrylamide gel, followed
by ethidium bromide staining.We obtained 311- and a 231-bp product
with the RNA and internal standard, respectively.
2.15. LPS binding assay
The ability of the peptides to neutralize LPS was determined using
a commercially available Limulus amebocyte lysate (LAL) assay
(Kinetic-QCL 1000 kit; BioWhittaker, Walkersville, MD, USA) [38,39].
Fig. 2. Inhibition of antimicrobial activity of the peptides by trypsin assessed using the radial diffusion assay (A) and broth microdilution assay (B) methods.
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of E. coli O55:B5 LPS containing 0.5 U/ml endotoxin for 30 min at
37 °C, followed by incubation with 50 μl of amoebocyte lysate reagent
for 10 min. Absorbance at 405 nm was measured 10 and 16 min after
the addition of 100 μl of the chromogenic substrate, Ac-Ile-Glu-Ala-
Arg-p-nitroanilide. The amount of non-bound LPS was extrapolated
from a standard curve, and percentage inhibition calculated as:
[(amount of free LPS in control samples)−(amount of free LPS in test
samples)]×100/amount of free LPS in control samples.
3. Results
3.1. Antimicrobial activity
Compared to the natural AMP IN, four Trp-rich peptides (K8W3,
K7LW3, K6L2W3 and K5L3W3) with +6 to +9 net positive chargesTable 5
Tryptophan emission maxima of 3 μM solutions of peptides in the presence of 0.6 mM
EYPE/EYPG (7:3, w/w) SUVs, and 0.6 mM EYPC/cholesterol (10:1, w/w) SUVs.
Peptide Tris–HCl buffer
(nm)
EYPE/EYPG
(7:3, w/w) (nm)
EYPC/cholesterol
(10:1, w/w) (nm)
K8W3 350.0 338.6 (11.4) 350.0 (0.0)
K7LW3 351.4 337.4 (14.0) 351.4 (0.0)
K6L2W3 350.6 337.4 (13.2) 347.0 (3.6)
K5L3W3 350.2 335.4 (14.8) 341.0 (9.2)
K4L4W3 350.6 334.4 (16.2) 336.4 (14.2)
K3L5W3 349.8 334.0 (15.8) 336.8 (13.0)
K2L6W3 348.2 336.4 (11.8) 338.6 (9.6)
R8W3 351.0 340.6 (10.4) 346.6 (4.0)
R7LW3 350.0 341.8 (8.2) 346.6 (3.4)
R6L2W3 350.0 338.0 (12.0) 340.8 (9.2)
O6L2W3 350.6 339.4 (11.2) 346.4 (4.2)
O6X2W3 352.0 338.8 (13.2) 344.8 (7.2)
K6L2W3-D 350.2 335.4 (14.8) 344.4 (5.8)
R6L2W3-D 350.2 338.4 (11.8) 340.0 (10.2)
Indolicidin (IN) 350.0 337.4 (12.6) 341.0 (9.0)displayed approximately 2-fold higher antimicrobial activities. The
order of antimicrobial activity was K6L2W3NK7LW3, K5L3W3NK8W3-
5L3W3NK8W3NK4L4W3N INNK3L5W3 K2L6W3 (Table 2). Lys-containing
peptides(K8W3,K7LW3andK6L2W3) showedapproximately2- to4-fold
higher antibacterial activities than did the counterpart Arg-containing
peptides (R8W3, R7LW3 and R6L2W3). O6L2W3, O6X2W3, K6L2W3-D and
R6L2W3-D were 1.5-, 1.3-, 1.8-, and 1.5-fold less active than K6L2W3,
respectively. R6L2W3-D was 1.5-fold more active than R6L2W3.
3.2. Hemolytic activity
K8W3, K7LW3 and K6L2W3 did not cause any hemolysis when
present at concentrations up to 400 μM. In contrast, K5L3W3, K4L4W3,
K3L5W3 and K2L6W3 induced signiﬁcant hemolysis (5%) at 100 μM,
6.25 μM, 3.125 μM, and 1.56 μM, respectively (Table 3). The order ofFig. 3. Dose-dependent peptide-induced calcein release from negatively charged EYPE/
EYPG (7:3, w/w) LUVs. The percentage of dye leakage caused by a peptide was
calculated as follows: % Dye leakage=100×[(F−F0)/(Ft−F0)], where F is the leaked
ﬂuorescence intensity achieved 5 min after addition of peptide, and F0 and Ft are the
intensities seen without the peptide and with Triton X-100 (full leakage; positive
control), respectively. Peptides are indicated as follows: K6L2W3 (●), K6L2W3-D (○),
R6L2W3 (▾), R6L2W3-D (▿), and Indolicidin (■).
Fig. 4. Confocal laser-scanning microscopy of E. coli treated with FITC-labeled peptides. The cells were treated with 10 μg/ml of FITC-labeled K6L2W3 (A), FITC-labeled R6L2W3 (B),
FITC-labeled K6L2W3-D (C), FITC-labeled R6L2W3-D (D), FITC-labeled IN (E), or FITC-labeled buforin-2 (F).
Fig. 5. Interaction of the peptides with plasmid DNA. Binding was assayed bymeasuring
inhibition of plasmid DNA (100 ng; pBluscriptII SK+)migration. DNA and peptides were
co-incubated for 1 h at room temperature before electrophoresis on a 1.0% (w/v) agarose
gel. Lane 1, plasmid DNA alone; lane 2, with 1 μM peptide; lane 3, with 2.5 μM peptide;
lane 4, with 5 μM peptide; lane 5, with 10 μM peptide; and lane 6, with 20 μM peptide.
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2L6W3NK3L5W3NK4L4W3N INNK5L3W3 K8W3, K7LW3, K6L2W3 (Table
3). Interestingly, K6L2W3 displayed no hemolytic activity up to 400 μM,
but the counterpart Arg-containing peptide, R6L2W3 displayed
hemolytic activity at 400 μM. O6L2W3 did not cause any hemolysis
even at 400 μM, but O6X2W3, K6L2W3-D, and R6L2W3-D induced
signiﬁcant hemolysis at 400 μM, 400 μM, and 200 μM, respectively.
The retention time of peptides on a reverse-phase matrix was
reported to be related to peptide hydrophobicity [40,41]. The
relationships of the cationicity and hydrophobicity of our designed
peptides between antimicrobial activity and hemolytic activity were
investigated. Our results indicated that the cationicity of peptides is
closely related to their antimicrobial activity and the hydrophobicity is
in very good agreement with their hemolytic activity (Fig. 1).
3.3. Cell speciﬁcity/therapeutic index
To assess the cell speciﬁcity of the model peptides, we calculated
the therapeutic index (TI), a widely accepted measurement of the cell
speciﬁcity of an antimicrobial agent [42,43]. The therapeutic index of
each peptide was calculated as the ratio of minimal hemolytic
concentration (MHC) to GM. GM is the geometric mean of the MIC
values seen when the peptides acted upon six bacterial strains (Table
3). The MHC is deﬁned as the peptide concentration that produces 5%
hemolysis. When no hemolytic activity was detectable at the highest
concentration (400 μM) tested, an MHC of 800 μM was employed for
therapeutic index calculation. A larger therapeutic index value
corresponds to greater cell speciﬁcity. The therapeutic index of natural
IN was 10.4, indicating relatively poor cell speciﬁcity. The therapeutic
indices of K8W3, K7LW3 and K6L2W3 were 320.0, 363.6, and 400.0
respectively. In particular, K6L2W3 had the highest therapeutic index
(∼40-fold increase compared with IN). In contrast, K4L4W3, K3L5W3,
and K2L6W3 had very low therapeutic indices (between 0.1 and 1.9).Compared to Arg-containing peptides (R8W3, R7LW3 and R6L2W3), the
counterpart Lys-containing peptides (K8W3, K7LW3 and K6L2W3)
showed approximately a 2- to 4-fold higher cell speciﬁcity/therapeu-
tic index than that of IN. In addition, the other peptides with unusual
Fig. 6. Cytotoxicity of peptides against macrophage-derived RAW264.7 cells. Peptides are indicated as follows: (A) K8W3 (●), K7LW3 (○), K6L2W3 (▾), K5L3W3 (▿), K4L4W3 (■),
K3L5W3 (□), K2L6W3 (♦). (B) R8W3 (●), R7LW3 (○), R6L2W3 (▾), O6L2W3 (▿), O6X2W3 (■), K6L2W3-D (□), R6L2W3-D (♦), and Indolicidin (◊).
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relatively high therapeutic indices between 111.1 and 266.6.
3.4. Antimicrobial activity against antibiotic-resistant clinical isolates
The antimicrobial activities of the model peptides against
antibiotic-resistant clinical isolates were examined, to assess potential
peptide usefulness as therapeutic agents (Table 4). Except for K2L6W3,
all model peptides displayed higher antimicrobial activities than did
IN against two methicillin-resistant Staphylococcus aureus (MRSA)Fig. 7. Inhibitory effects of peptides on LPS-induced nitric oxide (NO) production in RAW264.
or the ﬁxed concentration (10 µM) (A) and the various concentrations (1, 2.5, 5,10 and 20 μM
of nitrite released within them was measured. The error bars represent standard deviationsstrains and two multidrug-resistant Pseudomonas aeruginosa
(MDRPA) strains.
3.5. Resistance to proteolytic digestion
A major limitation of antimicrobial peptide is inactivation by
proteases. Poor protease stability severely limits the clinical use of
many therapeutic peptides [19,44]. We examined the susceptibility of
peptides to trypsin. Trypsin speciﬁcally catalyzes the hydrolysis of C-
terminal amide bonds of Lys and Arg, making the enzyme ideal for our7 cells. RAW264.7 cells (5×105 cells/ml) were treated with 20 ng/ml LPS in the absence
) (B) of the peptides for 24 h. The cell culturemediawere then collected, and the amount
of the mean determined from three independent experiments.
Fig. 8. Inhibitory effects of peptides on LPS-induced iNOS mRNAs expression in RAW264.7 cells. RAW264.7 cells (5×105 cells/well) were incubated with peptides (10 μM) in the
presence of LPS (20 ng/ml) for 8 h. Total RNA was isolated and analyzed for expression of iNOS mRNA by RT-PCR. One of two representative experiments is shown.
Fig. 9. LPS binding activity of the peptides. E. coli-derived LPS (E. coli O111:B4 LPS)
(0.5 U/ml endotoxin) was incubated with various concentrations of each peptide for
30 min, and the amount of free LPS was determined using the Limulus amebocyte lysate
assay. Peptides are indicated as follows: K6L2W3 (●), K5L3W3 (○), K6L2W3-D (▾),
R6L2W3 (▿), O6L2W3 (■), O6X2W3 (□), LL-37 (♦), Indolicidin (◊), and Polymyxin B (▲).
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possess several Lys or Arg residues. The assay was also used to
examine whether peptides substituted with all D-amino acids, or with
some Orn or/and Nle residues, might be stable to protease treatment.
IN, K6L2W3, R6L2W3, K6L2W3-D, R6L2W3-D O6L2W3, and O6X2W3 were
pretreated with trypsin and their residual antimicrobial activities
assayed using the radial diffusion assay method and the broth
microdilution assay method. As shown in Fig. 2, trypsin treatment of
K6L2W3, R6L2W3, and IN with L-type amino acids abolished anti-
microbial activities against both E. coli and S. aureus. However, the
antimicrobial activities of K6L2W3-D and R6L2W3-D composed of D-
type amino acids were stable even after trypsin treatment. In addition,
trypsin treatment of O6L2W3 and O6X2W3 containing Orn or/and Nle,
only partially decreased antimicrobial activity. These data reveal that
substitutionwith unusual amino acids such as D-type amino acids, Orn
or Nle, may allow sensitivity to enzymatic degradation to be
controlled.
3.6. Tryptophan ﬂuorescence blue shift in model membranes
When excited at 280 nm, Trp residues in the peptides, in aqueous
buffer gave rise to an emission peak centered at 350 nm. When the
peptides bound to phospholipids, the more hydrophobic environment
and the decreased ﬂexibility of the Trp residues caused a shift in this
emission to lower wavelengths (the blue shift) (Table 5). In negatively
charged EYPE/EYPG (7:3, w/w) SUVs, ﬂuorescence emission maxima
of all peptides exhibited a large blue shift, indicating that the peptides
penetrated into the hydrocarbon region of the bilayer. In zwitterionic
EYPC/cholesterol (10:1, w/w) SUVs, K8W3 and K7LW3 induced no blue
shift in ﬂuorescence emission maxima. In contrast, K6L2W3, R8W3,
R7LW3, O6L2W3, and K6L2W3-D caused moderate blue shift (3.4–
5.8 nm), and the other peptides showed large blue shifts (7.2–
14.2 nm). Compared to Lys-containing peptides (K8W3, K7LW3 and
K6L2W3), the counterpart Arg-containing peptides (R8W3, R7LW3 and
R6L2W3) showed larger blue shifts. Similar ﬁndings were observed in
tritrpticin and analogs containing multiple Lys or Arg residues [15].
These results suggest that multiple Lys-containing peptides interact
more weakly with zwitterionic phospholipids than do their multiple
Arg-containing counterparts.
3.7. Calcein leakage from negatively charged model membranes
To examine whether the antimicrobial activities of K6L2W3,
R6L2W3, K6L2W3-D and R6L2W3-D might depend on peptide ability
to permeate bacterial membranes, we measured the inﬂuence of
peptides on calcein leakage from negatively charged EYPE/EYPG (7:3
w/w) LUVs (a bacterial membrane-mimicking environment) (Fig. 3).
IN was able to cause almost complete leakage of calcein at peptide/
lipid molar ratio of 0.1, whereas K6L2W3, R6L2W3, K6L2W3-D and
R6L2W3-D caused less than 40% dye leakage.
3.8. Confocal laser-scanning microscopy
To more precisely examine the localization of K6L2W3, R6L2W3,
K6L2W3-D and R6L2W3-D, FITC-labeled peptides were incubatedwith E. coli and peptide distribution in the bacteria was investigated
by confocal laser-scanning microscopy (Fig. 4). The antimicrobial
activity of FITC-labeled peptides was identical to that of FITC-
unlabeled peptides (data not shown). FITC-labeled K6L2W3, R6L2W3,
K6L2W3-D and R6L2W3-D were found to penetrate the cell
membrane and to accumulate inside E. coli, as observed for
buforin-2, indicating that the cytoplasm is the major site of action
of these peptides. In contrast, FITC-labeled IN did not enter the cell
membrane.
3.9. DNA binding activity
To clarify the molecular mechanism of peptide action, we
examined the DNA-binding properties of peptides (Fig. 5). DNA
binding was examined by analyzing the electrophoretic mobility of
DNA bands, at various ratios of peptide to DNA, on an agarose gel (1%,
w/v), following earlier protocols used for testing of different
antimicrobial peptides [45]. K6L2W3, R6L2W3, K6L2W3-D, and
R6L2W3-D inhibited DNAmigration at 5–10 μM. Buforin-2 signiﬁcantly
inhibited DNA migration at 20 μM, but IN did not inhibit DNA
migration even at 20 μM.
3.10. Cytotoxicity
The cytotoxicities of peptides on RAW264.7 macrophage cells
were evaluated by the standard MTT assay, which demonstrates
active energization of cells and is conventionally used as a measure
of cell viability. The result is shown in Fig. 6. Except for K4L4W3,
K3L5W3, K2L6W3, and R6L2W3-D, no peptides exhibited signiﬁcant
cytotoxicity at 10 μM, as also observed for IN and LL-37.
Furthermore, none of K8W3, K7LW3, K6L2W3, R8W3, or R7LW3
exhibited any cytotoxicity even at 40 μM. Peptides showing no
cytotoxicity at 10 μM were used in the experiments described
below.
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Nitric oxide (NO) is one of the important inﬂammatory products
and primarily involved in promoting inﬂammatory response. To assess
the cells were treated with or without 20 ng/ml LPS at ﬁxed or various
concentration of peptides. Cell culture media were collected and
stored at −70 °C. K5L3W3, R6L2W3, O6L2W3, O6X2W3, and K6L2W3-D
inhibited almost 100% of NO production at 10 μM, as observed for LL-
37 and IN used as positive control peptides, but K6L2W3 inhibited
approximately 50% of NO production at 10 μM. In contrast, K8W3,
K7LW3, R8W3, and R7LW3 had little effect on NO production at 10 μM
(Fig. 7A). In addition, K5L3W3, R6L2W3, O6L2W3, O6X2W3, and K6L2W3-
D concentration-dependently inhibited NO production, with poten-
cies similar to those shown by LL-37 and IN (Fig. 7B).
3.12. Inhibition of LPS-induced iNOS gene expression
LPS induces the expression of iNOS protein in macrophages, which
correlates with NO production, so the effects of peptides on LPS-
induced iNOS gene expression (LPS: 20 ng/ml) induced in LPS-
stimulated RAW264.7 macrophage cells were examined over 6 h.
K6L2W3, K5L3W3, R6L2W3, O6L2W3, O6X2W3, and K6L2W3-D at 10 μM
completely suppressed iNOS gene expression. As expected, K8W3 and
R8W3, which showed no inhibition of NO production, failed to exert
any inhibitory effect on iNOS gene expression (Fig. 8). These data are
in agreement with the NO production inhibition results of Fig. 7.
3.13. LPS binding activity
To determine whether the peptides might neutralize LPS at
bactericidal concentrations, increasing concentrations of peptides
were incubated with LPS and the resulting mixtures assessed using
the LAL assay. K6L2W3, K5L3W3, R6L2W3, O6L2W3, O6X2W3, and
K6L2W3-D displayed nearly complete LPS binding at 5 mM, as also
observed for polymyxin B, IN and LL-37 (Fig. 9).
4. Discussion
In the present study, we successfully designed novel 11-meric Trp-
rich model antimicrobial peptides with higher cell speciﬁcity than
shown by the Trp-rich natural antimicrobial peptide, IN. We included
only Trp, Lys/Arg, and Leu residues. K8W3, K7LW3 and K6L2W3
displayed relatively high cell speciﬁcity/therapeutic index. In parti-
cular, K6L2W3 exhibited the highest therapeutic index of 400.0
(approximately 40 times that of IN).
Although antimicrobial peptides showgreat structural diversity, all
are cationic, because they have multiple Arg and/or Lys residues. This
cationic property is very important for binding to negatively charged
surfaces of bacteria lipid membranes. It has been reported that
Arg→Lys substitution in a Trp-rich antimicrobial peptide, tritrpticin
and an analog, increased cell speciﬁcity by enhancing antimicrobial
activity and reducing hemolytic activity [15]. Also the effects of Lys
and Arg residues of our Trp-rich model peptides on cell speciﬁcity
were examined. As in previous report [15], Lys-containing peptides
(K8W3, K7LW3, and K6L2W3) showed approximately 2- to 4-fold
higher cell speciﬁcities than did their counterpart Arg-containing
peptides (R8W3, R7LW3, and R6L2W3). These results suggest that
multiple Lys residues are more important than multiple Arg residues
in the design of antimicrobial peptides with improved cell speciﬁcity.
In addition, the peptides were also very active against several clinical
isolates, including MRSA and MDRPA, indicating that they may be
promising lead compounds for the design of pharmaceuticals to
overcome bacterial antibiotic resistance.
It has been known that the cell speciﬁcity of AMPs is mainly
governed by the cationicity (net positive charge) and hydrophobicity
of peptides, and there should be a proper balance between cationicityand hydrophobicity of peptides to retain potent antimicrobial
peptides and avoid hemolytic activity [9–12]. Like other previous
reports, the increase in cationicity of peptides promotes antimicrobial
activity, whereas increases in hydrophobicity promote hemolytic
activity. Among our designed Trp-rich peptides, K6L2W3 had the most
moderate cationicity and hydrophobicity to show potent antimicro-
bial activity and no hemolytic activity.
The suppression of antimicrobial peptide activity by proteolytic
digestion has hampered efforts to develop safe and effective peptides
for clinical use [19,44]. K6L2W3 and R6L2W3 composed of L-amino
acids, were completely digested by trypsin. To increase proteolytic
stability, Orn, Nle or D-type amino acids were substituted for L-amino
acids of K6L2W3 and R6L2W3. The resulting analogs (O6L2W3, O6X2W3,
K6L2W3-D, and R6L2W3-D) retained complete and partial antimicro-
bial activity even after trypsin treatment. Therefore, these peptides are
candidate for clinical therapeutic use.
Most antimicrobial peptides have cationic and amphipathic
properties and membrane disruption or pore/ion channel formation
in cytoplasmic membranes of susceptible bacteria has been
postulated as the main mode of action (i.e., the membrane-targeting
mechanism) [46,47]. Other mechanisms of action have been
reported, including inhibition of cellular functions by binding to
DNA, RNA, and proteins, and the inhibition of DNA, RNA, and/or
protein synthesis (i.e., the intracellular-targeting mechanism). For
example, buforin-2, a cationic α-helical peptide isolated from the
stomach of the Asian toad Bufo bufo gargarizans, exerts bactericidal
activity, can penetrate cell membranes without lying susceptible
bacteria, and binds more strongly to DNA and RNA than does
magainin 2, [45,48]. PR-39 is bacteriostatic to Gram-negative
bacteria and does not induce membrane lysis, nor does kill bacteria
by a non-pore forming mechanism. Rather, PR-39 kills bacteria by a
mechanism that stops protein and DNA synthesis after a lag period
of about 8 min [49–51]. These results indicated that the anti-
microbial actions of buforin-2 and PR-39 are in the class of
intracellular target mechanisms.
A low ability to facilitate ﬂuorescent marker escape from bacterial
membrane-mimicking vesicles suggested that the principal bacter-
icidal activities of several peptides (K6L2W3, R6L2W3, K6L2W3-D, and
R6L2W3-D) might occur at sites inside bacteria. Therefore, to
determine whether the peptides entered the bacterial cell membrane,
visualization by confocal laser-scanning microscopy of FITC-labeled
peptides was conducted. FITC-labeled K6L2W3, R6L2W3, K6L2W3-D and
R6L2W3-D penetrated the cell membrane and accumulated in the
cytoplasm of E. coli, as observed for buforin-2, whereas FITC-labeled
IN did not enter the cell membrane. Furthermore, in gel retardation
assays, we conﬁrmed that K6L2W3, R6L2W3, K6L2W3-D and R6L2W3-D
bound more strongly to DNA than did IN, as also seen with buforin-2.
Taken together, these results suggest that a possible antimicrobial
action mechanism of K6L2W3, R6L2W3, K6L2W3-D, and R6L2W3-D may
be related to the inhibition of intracellular functions via interference
with DNA/RNA synthesis.
Furthermore, to investigate whether our peptides might have anti-
inﬂammatory activities when incubated with immune cells, as well as
potent bactericidal activities, we examined the inhibition of the
release of NO and iNOS mRNA expression by peptides in LPS-
stimulated mouse macrophage RAW264.7 cells. Among our designed
peptides, some, including K5L3W3, K6L2W3, R6L2W3, O6L2W3, O6X2W3,
and K6L2W3-D suppressed LPS-induced inducible nitric oxide
synthase (iNOS) mRNA expression and inhibited release of nitric
oxide (NO) following LPS stimulation in RAW264.7 cells. In addition,
these peptides had powerful LPS binding activities at bactericidal
concentrations.
In conclusion, we successfully designed novel short Trp-richmodel
AMPs possessing high cell speciﬁcities and anti-inﬂammatory
activities. These Trp-rich model AMPs have potential for future
development as novel antimicrobial and anti-inﬂammatory peptides.
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